Registration Options

Register for the meeting.

Session Time and Location

Date: Tuesday, 04/26/2022

Time: 3:00 PM (view in the schedule)

Room: TBD

Target Audience

If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric and/or neurological patients, we invite you to participate in this online course.

Session Summary

Tourette’s Disorder (TD) is a chronic neurological disorder with age of onset prior to 18 years. The hallmark symptoms are repetitive, stereotyped movements and vocalizations called tics that wax and wane. The overall prevalence of TD in children has been reported at 7.7 per 1000 school-aged children. Tics initially present between the ages of 8 and 12 years, followed by a gradual decrease throughout adolescent and young adulthood. Approximately 20% of patients do not experience a decrease in tics and some of these patients might also go on to develop the most severe and debilitating forms of complex tics. There is currently no cure while symptomatic FDA-approved or off-label treatment is available; additionally, there are some potential new pharmacological treatments under investigation. However, there is no treatment that has proven efficacious for symptom suppression in all individuals with TD, likely due to phenotypic variabilities. Different psychiatric comorbidities are common and treatment strategies must take into consideration comorbidity-related treatment goals. This program will provide the most up-to-date information regarding clinical presentation, diagnosis, and treatment options and challenges for TD with or without comorbid OCD and ADHD in order to provide competent patient-centered care grounded in evidence for individuals with TD.

Faculty Information and Disclosures

Learning Objectives

  1. Review recent updates on genomics and clinical phenomenology of Tourette’s Disorder (TD).
  2. Discuss the efficacy and safety of available behavioral and pharmacologic treatment modalities and their place in therapy.
  3. Describe considerations for TD management in the presence of psychiatric comorbidities including attention-deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD).
  4. Identify a pharmacotherapy treatment plan for an individual with TD.

Continuing Education Credit and Disclosures

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.